Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nuclear Medicine Review
MENU
Shortcuts Submit an article Author Guidelines (new) Ahead Of Print Editorial Board Reviewers 2018

open access

Vol 14, No 2 (2011)
Original articles
Published online: 2012-01-04
Submitted: 2012-01-23
View PDF Download PDF file
Get Citation

In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles

Andras Polyak, Elena Alina Palade, Lajos Balogh, Zita Postenyi, Veronika Haasz, Gergely Janoki, Gyozo A. Janoki
Nucl. Med. Rev 2011;14(2):55-62.

open access

Vol 14, No 2 (2011)
Original articles
Published online: 2012-01-04
Submitted: 2012-01-23

Abstract

BACKGROUND: Nanoparticles represent promising drug carrier systems. In the case of cytostatics such as doxorubicin, carrier colloid systems as human serum albumin (HSA) nanoparticles, may increase their therapeutic efficiency and decrease their side-effects (toxicity) and any potential multidrug resistance. In the present study, doxorubicin, as a widely used antineoplastic agent, was incorporated into the matrix of human serum albumin and three different particle-sized doxorubicin-loaded HSA nanoparticles were prepared, using a previously described desolvation method. Our objective was to find out if different particle sizes of colloid carriers can allow regarding the given cytostatic agent.
MATERIAL AND METHODS: The three prepared nanoparticles were labelled using technetium (Tc-99m) and were tested for their physicochemical colloidal quality, fluctuations, and radiochemical stability. Biodistribution of different-sized radiolabelled colloids were determined by means of scintigraphic imaging studies in healthy male Wistar rats. Images were taken by gamma camera at several times and organ uptakes were estimated by quantitative ROI analysis.
RESULTS: In vitro measurements showed that more than 95% of doxorubicin proportion was permanently adsorbed to human serum albumin. Radiolabelled doxorubicin-loaded particles had high-degree and durable labelling efficiency and particle size stability. Biodistribution results had a close correlation to earlier described results of radiocolloids in similar particle size ranges. In vivo examinations verified that colloid carriers have insignificant size fluctuations after an intravenous application and they show the proper distribution according to their particle size.
CONCLUSIONS: Our investigations verified that different and stable particle sizes make drug carrier HSA nanoparticles possible to apply different drug targeting in a potential clinical use.
Nuclear Med Rev 2011; 14, 2: 55–62

Abstract

BACKGROUND: Nanoparticles represent promising drug carrier systems. In the case of cytostatics such as doxorubicin, carrier colloid systems as human serum albumin (HSA) nanoparticles, may increase their therapeutic efficiency and decrease their side-effects (toxicity) and any potential multidrug resistance. In the present study, doxorubicin, as a widely used antineoplastic agent, was incorporated into the matrix of human serum albumin and three different particle-sized doxorubicin-loaded HSA nanoparticles were prepared, using a previously described desolvation method. Our objective was to find out if different particle sizes of colloid carriers can allow regarding the given cytostatic agent.
MATERIAL AND METHODS: The three prepared nanoparticles were labelled using technetium (Tc-99m) and were tested for their physicochemical colloidal quality, fluctuations, and radiochemical stability. Biodistribution of different-sized radiolabelled colloids were determined by means of scintigraphic imaging studies in healthy male Wistar rats. Images were taken by gamma camera at several times and organ uptakes were estimated by quantitative ROI analysis.
RESULTS: In vitro measurements showed that more than 95% of doxorubicin proportion was permanently adsorbed to human serum albumin. Radiolabelled doxorubicin-loaded particles had high-degree and durable labelling efficiency and particle size stability. Biodistribution results had a close correlation to earlier described results of radiocolloids in similar particle size ranges. In vivo examinations verified that colloid carriers have insignificant size fluctuations after an intravenous application and they show the proper distribution according to their particle size.
CONCLUSIONS: Our investigations verified that different and stable particle sizes make drug carrier HSA nanoparticles possible to apply different drug targeting in a potential clinical use.
Nuclear Med Rev 2011; 14, 2: 55–62

Full Text:

View PDF Download PDF file
Get Citation

Keywords

doxorubicin; HSA; Tc-99m; nanoparticle; colloid; labelling; biodistribution

About this article
Title

In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles

Journal

Nuclear Medicine Review

Issue

Vol 14, No 2 (2011)

Pages

55-62

Published online

2012-01-04

Bibliographic record

Nucl. Med. Rev 2011;14(2):55-62.

Keywords

doxorubicin
HSA
Tc-99m
nanoparticle
colloid
labelling
biodistribution

Authors

Andras Polyak
Elena Alina Palade
Lajos Balogh
Zita Postenyi
Veronika Haasz
Gergely Janoki
Gyozo A. Janoki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl